This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

British orthopedic surgeons are a skeptical group, and when it comes to chemoprophylaxis for venous thromboembolism, strong opinions are guaranteed to emerge, especially in the light of a new anticoagulant. The editorial by Heit¹ clearly highlights the clinical and economic arguments for thromboprophylaxis and succinctly outlines the potential benefits and shortcomings of fondaparinux compared with low-molecular-weight heparin.¹ Fondaparinux offers a benefit with an overall 50% reduction in venographic deep vein thrombosis, but without reduction in symptomatic end points at day 11 or in fatal and nonfatal pulmonary embolism and mortality at day 49.² Even if the venographic reductions translated into fractional reductions in clinical end points, such a marginal reduction must be balanced against an absolute 1% increase in bleeding.^{1, 3} Safety is the central concern of surgeons in the United Kingdom, not marginal increases in efficacy. One of the fondaparinux studies investigated hip fracture and highlighted the need for improved . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

DEPRESSION IN OLDER MEDICAL INPATIENTS
Rozzini et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2007;62:796-797.
FULL TEXT